Welcome to clinical site selection and evaluation Part 2, where we continue the conversation on optimizing clinical site selection and evaluation. In this episode Linda Peterson and Julie Sheidy share recommendations on how to approach site selection, how to build teams, how to communicate within organizations and across teams, and their approach to site identification.
Key takeaways include:
3:00 – How can the site and sponsor work together to accelerate site selection?
5:15 – Julie describes the traits, skills, and characteristics of a “dream team” from CRO or Sponsor perspective and from the site’s perspective.
8:45 – In the event that a CRO or Sponsor identifies a lack of resources at a particular site, is there an advantage to the CRO or Sponsor supplementing those resources?
10:50 – The importance of strong communication within and between the CRO and site “dream teams.”
14:15 – Tips for maintaining a good working relationship and culture through turnover or staffing changes.
16:30 – Best practices for site identification and site selection in the case of rare disease trials and/or common chronic disease trials.
19:15 – How do you address potential site-related bias or the impact of advanced expertise when considering major center or world-class research institutions? How do you ensure the findings are applicable to all care settings if you are conduct research at elite institutions?
20:15 – Can or should sites advocate for altering a protocol or research question to better fit the population or their specific patient population?
This episode of Chasing Compliance is for those working on regulatory submissions for in-vitro diagnostic (IVD) medial devices. Today we talk to our resident...
This episode is Part 2 of a two-part episode on Abbreviated New Drug Applications (ANDAs). We continue our conversation with our ANDA expert Sandra...